Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...
Business Insider1d
Madrigal Pharmaceuticals price target raised to $236 from $194 at B. Riley
B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout” print ...
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...
FiercePharma6d
It's a monster MASH for Madrigal as Rezdiffra has caught on in a flash
In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...
MONTCO.Today on MSN2d
Conshohocken’s Madrigal Pharmaceuticals Reports Sales Through the Roof
Conshohocken’s Madrigal Pharmaceuticals, saw third-quarter sales soar for its NASH treatment, Rezdiffra, writes John George ...
Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations
Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...
Zacks.com on MSN5d
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
Madrigal Pharmaceuticals MDGL reported third-quarter 2024 loss of $4.92 per share, narrower than the Zacks Consensus Estimate ...
STAT5d
A setback for the tau approach to Alzheimer’s
In the effort to expand approaches to treating Alzheimer’s beyond targeting amyloid, some companies have sought to target ...
Montgomery County firm's shares soar on huge sales increase of flagship drug
Sibold credited Rezdiffra's sales growth to the growing adoption of the treatment by prescribers, broader payer coverage for ...
Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings
Madrigal Pharmaceuticals' Rezdiffra for NASH shows strong early demand, positioning the company as a market leader. Read why ...
Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ...
Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...
ETF Daily News3d
Madrigal Pharmaceuticals (NASDAQ:MDGL) Sees Unusually-High Trading Volume Following Strong Earnings
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) saw unusually-high trading volume on Friday following a better than expected earnings announcement.Approximately 560,141 shares ...